Drug
Retatrutide
Retatrutide: highest development phase Phase 3, developed by Eli Lilly. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Retatrutide NCT07232719 | Phase 3 | Obesity |
| Retatrutide NCT05936151 | Phase 2 | Overweight or Obesity |
Latest
Follow Retatrutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.